Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme

2017155 citationsJournal Articlebronze Open Access

Authors

Violeta Razanskaite · Southampton General Hospital

Marion Bettey · Southampton General Hospital

Louise Downey · Southampton General Hospital

Julia L. Wright · Bristol Clinical Commissioning Group

J Callaghan · Southampton General Hospital

Miles Rush · Southampton General Hospital

Simon Whiteoak

Abstract

A managed switching programme from originator infliximab to biosimilar CT-P13 in IBD, using a gain-share agreement, delivers significant cost savings and investment in clinical services while maintaining similar patient-reported outcomes, biochemical response, drug persistence, and adverse event profile.

Topics & Keywords

Publication Details

Published in: Journal of Crohn s and Colitis

Volume 11, Issue 6, pp. jjw216-jjw216

DOI: 10.1093/ecco-jcc/jjw216

Field-Weighted Citation Impact: 10.45

Command Palette

Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme

Authors

Abstract

Topics & Keywords

Publication Details